What are the EHA-ESMO guidelines for third-line and subsequent therapy to treat multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

EHA-ESMO guideline recommendations for third-line and subsequent therapy of MM include the following [132] :

  • For patients who have been exposed to, or whose MM is refractory to, both bortezomib and lenalidomide, recommended regimens are daratumumab/carfilzomib/dexamethasone, isatuximab/pomalidomide/dexamethasone, isatuximab/carfilzomib/dexamethasone, and elotuzumab/pomalidomide/dexamethasone.
  • Patients with t(11;14) MM that is refractory to lenalidomide and sensitive to proteasome inhibitors may be treated with venetoclax/bortezomib/dexamethasone, if available.
  • For triple-refractory patients, selinexor/dexamethasone or belantamab mafodotin monotherapy is recommended, if available.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!